The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
The company also said it has closed a new $25 million debt facility, and will use the proceeds to retire outstanding debt and bolster the launch of AlloSure.
The company also reported that its preliminary full-year 2016 revenues rose 27 percent year over year, thanks to steady sales in its QuickFISH business.
The company also reported it completed 244,000 Cologuard tests during 2016, a 134 percent increase from 2015.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
The company said it expects a 1 percent increase in 2016 revenues, but noted that the results were adversely affected by certain competitive pressures in Q4, among other problems.
The South San Francisco, California-based firm said instrument revenues fell 39 percent, driven by lower-than-average sales of its Helios mass cytometry system.
The company missed its expectations due to declining orders for its HiSeq 2500 and HiSeq 4000 instruments and one fewer order for its HiSeq X Ten system.
Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.
The release clarifies issues related to the timing of revenue recognition for transactions outside the US.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.